S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
Log in
NASDAQ:ACER

Acer Therapeutics Stock Forecast, Price & News

$2.85
-0.53 (-15.68 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.75
Now: $2.85
$3.40
50-Day Range
$2.86
MA: $3.67
$4.39
52-Week Range
$1.08
Now: $2.85
$5.84
Volume442,233 shs
Average Volume1.17 million shs
Market Capitalization$40.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.
Acer Therapeutics logo

Headlines

Acer Therapeutics EPS misses by $0.05
November 10, 2020 |  seekingalpha.com
LD Micro - 360 Companies Set to Present this Week
August 31, 2020 |  finance.yahoo.com
Acer Therapeutics EPS misses by $0.18
August 13, 2020 |  seekingalpha.com
Tuesday 7/28 Insider Buying Report: ACER, RBCAA
July 28, 2020 |  www.nasdaq.com
Insider Buys Acer Therapeutics's Shares
July 28, 2020 |  www.benzinga.com
Insider Buys Acer Therapeutics's Shares
July 28, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100
Employees20
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.82 per share

Profitability

Net Income$-29,420,000.00

Miscellaneous

Market Cap$40.78 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

716th out of 1,969 stocks

Pharmaceutical Preparations Industry

346th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$2.85
-0.53 (-15.68 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

Is Acer Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Acer Therapeutics stock.
View analyst ratings for Acer Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Acer Therapeutics?

Wall Street analysts have given Acer Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acer Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 126,100 shares, a decrease of 52.6% from the January 28th total of 265,900 shares. Based on an average trading volume of 818,100 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.3% of the shares of the stock are short sold.
View Acer Therapeutics' Short Interest
.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Acer Therapeutics
.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) released its quarterly earnings data on Sunday, February, 28th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.09.
View Acer Therapeutics' earnings history
.

How has Acer Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACER stock has decreased by 15.7% and is now trading at $2.85.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ACER?

3 brokers have issued 1 year price objectives for Acer Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Acer Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 250.9% from the stock's current price.
View analysts' price targets for Acer Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 45, Pay $436k)
  • Mr. Harry S. Palmin, COO & CFO (Age 51, Pay $382.4k)
  • Mr. John Michael Klopp, Chief Technical Officer (Age 46)
  • Mr. Donald R. Joseph J.D., Chief Legal Officer & Sec. (Age 67)
  • Mr. Bernie Paul, VP of HR
  • Mr. Jefferson E. Davis, Chief Bus. Officer (Age 54)
  • Mr. Matthew T. Seibt, Chief Commercial Officer (Age 50)
  • Mr. Jason Kneeland CPA, VP of Fin. & Controller

What is Jason Chen's approval rating as Acer Therapeutics' CEO?

64 employees have rated Acer Therapeutics CEO Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among Acer Therapeutics' employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (0.93%) and HighPoint Advisor Group LLC (0.24%). Company insiders that own Acer Therapeutics stock include Chris Schelling, Donald Joseph and Steve Aselage.
View institutional ownership trends for Acer Therapeutics
.

Which institutional investors are selling Acer Therapeutics stock?

ACER stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc..
View insider buying and selling activity for Acer Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Acer Therapeutics stock?

ACER stock was acquired by a variety of institutional investors in the last quarter, including HighPoint Advisor Group LLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Chris Schelling, Donald Joseph, and Steve Aselage.
View insider buying and selling activity for Acer Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $2.85.

How much money does Acer Therapeutics make?

Acer Therapeutics has a market capitalization of $40.78 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.

How many employees does Acer Therapeutics have?

Acer Therapeutics employs 20 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is www.acertx.com.

Where are Acer Therapeutics' headquarters?

Acer Therapeutics is headquartered at 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.